search
Back to results

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Primary Purpose

Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Doxorubicin Hydrochloride
Laboratory Biomarker Analysis
Pharmacological Study
Ribociclib
Sponsored by
OHSU Knight Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Soft Tissue Sarcoma

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pathologically confirmed diagnosis of intermediate or high-grade soft tissue sarcoma for which single-agent doxorubicin is appropriate therapy, including but not limited to:

    • Synovial sarcoma
    • Fibrosarcoma
    • Undifferentiated sarcoma
    • Liposarcoma
    • Leiomyosarcoma
    • Angiosarcoma
    • Malignant peripheral nerve sheath tumor
    • Pleomorphic rhabdomyosarcoma
    • Myxofibrosarcoma
    • Epithelioid sarcoma
    • Undifferentiated pleomorphic sarcoma
  • Locally advanced unresectable or metastatic disease with no standard curative therapy available
  • Archival tumor tissue retinoblastoma-associated protein (pRb) positive by immunohistochemistry (IHC)
  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
  • All races and ethnic groups will be included; for subjects between the ages of 12-18 years only, body surface area (BSA) must be >= 1.28 m^2
  • Ejection fraction of >= 50% by echocardiogram or multi-gated acquisition (MUGA) scan
  • Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of ribociclib
  • Willing to use adequate contraception throughout the study and for 3 weeks after study drug discontinuation
  • Meets the following standard 12-lead electrocardiography (ECG) parameters at screening (defined as the mean of the triplicate ECGs; ECGs done in triplicate do not have a defined interval between assessments):

    • Corrected QT using Fridericia's correction formula (QTcF) interval at screening < 450 msec for males and < 470 msec for females (using Fridericia's correction)
    • Resting heart rate =< 100 beats per minute (bpm)
  • Absolute neutrophil count (ANC) >= 1.5 K/cu mm
  • Platelets (no transfusion within prior 7 days) >= 100 K/cu mm
  • Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
  • Total bilirubin < institutional upper limit of normal (ULN), except for subjects with documented Gilbert's syndrome, for which =< 3.0 x ULN or direct bilirubin =< 1.5 x ULN
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT) in the absence of liver metastases: =< 2.5 x ULN; if the subject has liver metastases: < 5 x ULN
  • Serum creatinine < 1.7 mg/dL
  • Potassium within institutional normal limit (WNL)
  • Corrected calcium WNL
  • Magnesium WNL
  • International normalized ratio (INR) =< 1.5

    • Use of rivaroxaban, apixaban, edoxaban or warfarin is an exclusion criteria; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed
  • All prior treatment-related toxicities resolved to =< grade 1 or are determined to be clinically stable by the investigator
  • Has completed prior therapies according to the criteria below:

    • Cytotoxic chemotherapy - at least 21 days since last dose prior to first dose of ribociclib
    • Small molecule inhibitors - at least 14 days since last dose prior to first dose of ribociclib
    • Monoclonal antibodies - at least 3 half-lives since last dose prior to first dose of ribociclib; exception: denosumab for bony metastases is allowable
    • Immunotherapy (e.g. tumor vaccines) - at least 42 days since last dose prior to first dose of ribociclib
    • Radiation - at least 14 days since last dose prior to first dose of ribociclib
  • Able to swallow capsules
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Life expectancy > 3 months
  • Ability to understand and the willingness to sign a written informed consent document; subject has signed the informed consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements

Exclusion Criteria:

  • Subjects with low grade tumors (histologic grade 1/3)
  • Histologic diagnosis for which single-agent doxorubicin is NOT appropriate therapy, including but not limited to:

    • Alveolar or embryonal rhabdomyosarcoma
    • Ewings sarcoma or primitive neuroectodermal tumor (PNET)
    • Osteosarcoma
    • Gastrointestinal stromal tumor (GIST)
  • Prior systemic therapy with an anthracycline for any indication
  • Known hypersensitivity to any of the excipients of ribociclib or doxorubicin (including to peanut and soy)
  • Currently receiving any of the following that cannot be discontinued at least 7 days prior to starting study drug:

    • Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges
    • Medications with a narrow therapeutic window that are predominantly metabolized through CYP3A4/5
    • Herbal supplements, such as St. John's wort; the use of marijuana or its derivatives is allowed in States with statutes permitting the use of recreational or medical marijuana
  • Uncontrolled intercurrent medical condition including, but not limited to:

    • Uncontrolled infection
    • Symptomatic congestive heart failure (New York Heart Association [NYHA] class III-IV)
    • Acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening
    • Uncontrolled cardiac arrhythmia or arrhythmia requiring medication other than beta blocker
    • Psychiatric illness/social situations that would limit compliance with study requirements
    • Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, etc.)
  • Concurrent malignancy or malignancy within 3 years prior to starting study drug, except:

    • Malignancies that have completed therapy and are considered by their physician to be at less than 30% risk of relapse, or
    • Malignancies not requiring treatment (e.g., RAI stage 0 chronic lymphocytic leukemia [CLL])
  • Central nervous system (CNS) involvement unless they meet ALL of the following criteria:

    • At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment
    • Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea/vomiting/diarrhea, malabsorption syndrome, or major small bowel resection)
  • Known history of human immunodeficiency virus (HIV) infection (testing not mandatory); NOTE: HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ribociclib; in addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
  • Systolic blood pressure (SBP) > 160 mmHg or < 90 mmHg at screening; if initial screening SBP is outside of the eligible range, blood pressure may be re-checked after intervention; SBP must be documented as stable and within the eligible range prior to starting study drug
  • Currently receiving rivaroxaban, apixaban, endoxaban, warfarin or other warfarin derived anticoagulant; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed; if transitioning from a prohibited anticoagulant, a minimum washout of 7 days from last dose of the prohibited medication is required prior to ribociclib start
  • Participation in a prior investigational interventional study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
  • Major surgery within 14 days prior to starting study drug or has not recovered from surgical complications (tumor biopsy is not considered as major surgery)
  • History of congenital long QT syndrome or torsades de pointes
  • History of non-compliance to medical regimen or inability to grant consent
  • Pregnant or nursing (lactating) women; breastfeeding should be discontinued

Sites / Locations

  • OHSU Knight Cancer Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment (ribociclib, doxorubicin hydrochloride)

Arm Description

Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Incidence of dose limiting toxicities (DLTs) of adverse events
Will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03. All adverse events (AEs) will be tabulated and summarized by major organ category, grade, anticipation, and drug attribution. Serious adverse events (SAE) specific incidence and exact 95% confidence interval will be provided where appropriate.

Secondary Outcome Measures

Progression-free survival (PFS)
The Kaplan-Meier product limit method will be used to estimate PFS of the median PFS and PFS rates at clinically relevant time points will be provided with the 90% confidence interval (CI).
Objective response rate (ORR)
Will be defined as the proportion of patients who achieved a complete response or a partial response. Will be assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1. The ORR, along with exact two-sided 95% confidence intervals, will be reported for the study.
Incidence of adverse events, SAEs
Will be assessed by NCI CTCAE v 4.03. Analyses will be performed for all patients having received at least one dose of study drug. Serious adverse events, AEs will be summarized using descriptive statistics.
Incidence of dose modifications (interruptions, reductions, intensity) due to adverse events
Analyses will be performed for all patients having received at least one dose of study drug. AEs leading to withdrawal/dose interruptions/dose modification will be summarized using descriptive statistics.

Full Information

First Posted
December 5, 2016
Last Updated
August 14, 2023
Sponsor
OHSU Knight Cancer Institute
Collaborators
Novartis Pharmaceuticals, Oregon Health and Science University
search

1. Study Identification

Unique Protocol Identification Number
NCT03009201
Brief Title
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Official Title
A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
March 10, 2017 (Actual)
Primary Completion Date
October 8, 2019 (Actual)
Study Completion Date
June 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
OHSU Knight Cancer Institute
Collaborators
Novartis Pharmaceuticals, Oregon Health and Science University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This phase Ib trial studies the side effects and best dose of ribociclib when giving together with doxorubicin hydrochloride in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed by surgery (advanced). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and doxorubicin hydrochloride may work better in treating patients with soft tissue sarcoma.
Detailed Description
PRIMARY OBJECTIVE: I. To determine the recommended phase 2 dose (RP2D) of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas. SECONDARY OBJECTIVES: I. To assess preliminary anti-tumor activity of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas. II. To characterize the safety and tolerability of ribociclib in combination with doxorubicin. OUTLINE: This is a dose-escalation study of ribociclib. Patients receive ribociclib orally (PO) daily on days 1-7, and doxorubicin hydrochloride intravenously (IV) on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients without disease progression after 6 cycles receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up within 30 days and then every 12 weeks for 12 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Malignant Peripheral Nerve Sheath Tumor, Locally Advanced Myxofibrosarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Epithelioid Sarcoma, Metastatic Fibrosarcoma, Metastatic Liposarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Myxofibrosarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Undifferentiated (Embryonal) Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Soft Tissue Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment (ribociclib, doxorubicin hydrochloride)
Arm Type
Experimental
Arm Description
Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
Doxorubicin Hydrochloride
Other Intervention Name(s)
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex
Intervention Description
Given IV
Intervention Type
Other
Intervention Name(s)
Laboratory Biomarker Analysis
Intervention Description
Correlative studies
Intervention Type
Other
Intervention Name(s)
Pharmacological Study
Intervention Description
Correlative studies
Intervention Type
Drug
Intervention Name(s)
Ribociclib
Other Intervention Name(s)
Kisqali, LEE-011, LEE011
Intervention Description
Given PO
Primary Outcome Measure Information:
Title
Incidence of dose limiting toxicities (DLTs) of adverse events
Description
Will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03. All adverse events (AEs) will be tabulated and summarized by major organ category, grade, anticipation, and drug attribution. Serious adverse events (SAE) specific incidence and exact 95% confidence interval will be provided where appropriate.
Time Frame
Up to 21 days
Secondary Outcome Measure Information:
Title
Progression-free survival (PFS)
Description
The Kaplan-Meier product limit method will be used to estimate PFS of the median PFS and PFS rates at clinically relevant time points will be provided with the 90% confidence interval (CI).
Time Frame
From first dose of protocol therapy to time of documented radiographic and/or clinical disease progression or death from any cause, whichever occurs first, assessed up to 12 months
Title
Objective response rate (ORR)
Description
Will be defined as the proportion of patients who achieved a complete response or a partial response. Will be assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1. The ORR, along with exact two-sided 95% confidence intervals, will be reported for the study.
Time Frame
Up to 12 months
Title
Incidence of adverse events, SAEs
Description
Will be assessed by NCI CTCAE v 4.03. Analyses will be performed for all patients having received at least one dose of study drug. Serious adverse events, AEs will be summarized using descriptive statistics.
Time Frame
Up to 12 months
Title
Incidence of dose modifications (interruptions, reductions, intensity) due to adverse events
Description
Analyses will be performed for all patients having received at least one dose of study drug. AEs leading to withdrawal/dose interruptions/dose modification will be summarized using descriptive statistics.
Time Frame
Up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathologically confirmed diagnosis of intermediate or high-grade soft tissue sarcoma for which single-agent doxorubicin is appropriate therapy, including but not limited to: Synovial sarcoma Fibrosarcoma Undifferentiated sarcoma Liposarcoma Leiomyosarcoma Angiosarcoma Malignant peripheral nerve sheath tumor Pleomorphic rhabdomyosarcoma Myxofibrosarcoma Epithelioid sarcoma Undifferentiated pleomorphic sarcoma Locally advanced unresectable or metastatic disease with no standard curative therapy available Archival tumor tissue retinoblastoma-associated protein (pRb) positive by immunohistochemistry (IHC) Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria All races and ethnic groups will be included; for subjects between the ages of 12-18 years only, body surface area (BSA) must be >= 1.28 m^2 Ejection fraction of >= 50% by echocardiogram or multi-gated acquisition (MUGA) scan Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of ribociclib Willing to use adequate contraception throughout the study and for 3 weeks after study drug discontinuation Meets the following standard 12-lead electrocardiography (ECG) parameters at screening (defined as the mean of the triplicate ECGs; ECGs done in triplicate do not have a defined interval between assessments): Corrected QT using Fridericia's correction formula (QTcF) interval at screening < 450 msec for males and < 470 msec for females (using Fridericia's correction) Resting heart rate =< 100 beats per minute (bpm) Absolute neutrophil count (ANC) >= 1.5 K/cu mm Platelets (no transfusion within prior 7 days) >= 100 K/cu mm Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL Total bilirubin < institutional upper limit of normal (ULN), except for subjects with documented Gilbert's syndrome, for which =< 3.0 x ULN or direct bilirubin =< 1.5 x ULN Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT) in the absence of liver metastases: =< 2.5 x ULN; if the subject has liver metastases: < 5 x ULN Serum creatinine < 1.7 mg/dL Potassium within institutional normal limit (WNL) Corrected calcium WNL Magnesium WNL International normalized ratio (INR) =< 1.5 Use of rivaroxaban, apixaban, edoxaban or warfarin is an exclusion criteria; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed All prior treatment-related toxicities resolved to =< grade 1 or are determined to be clinically stable by the investigator Has completed prior therapies according to the criteria below: Cytotoxic chemotherapy - at least 21 days since last dose prior to first dose of ribociclib Small molecule inhibitors - at least 14 days since last dose prior to first dose of ribociclib Monoclonal antibodies - at least 3 half-lives since last dose prior to first dose of ribociclib; exception: denosumab for bony metastases is allowable Immunotherapy (e.g. tumor vaccines) - at least 42 days since last dose prior to first dose of ribociclib Radiation - at least 14 days since last dose prior to first dose of ribociclib Able to swallow capsules Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) Life expectancy > 3 months Ability to understand and the willingness to sign a written informed consent document; subject has signed the informed consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements Exclusion Criteria: Subjects with low grade tumors (histologic grade 1/3) Histologic diagnosis for which single-agent doxorubicin is NOT appropriate therapy, including but not limited to: Alveolar or embryonal rhabdomyosarcoma Ewings sarcoma or primitive neuroectodermal tumor (PNET) Osteosarcoma Gastrointestinal stromal tumor (GIST) Prior systemic therapy with an anthracycline for any indication Known hypersensitivity to any of the excipients of ribociclib or doxorubicin (including to peanut and soy) Currently receiving any of the following that cannot be discontinued at least 7 days prior to starting study drug: Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges Medications with a narrow therapeutic window that are predominantly metabolized through CYP3A4/5 Herbal supplements, such as St. John's wort; the use of marijuana or its derivatives is allowed in States with statutes permitting the use of recreational or medical marijuana Uncontrolled intercurrent medical condition including, but not limited to: Uncontrolled infection Symptomatic congestive heart failure (New York Heart Association [NYHA] class III-IV) Acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening Uncontrolled cardiac arrhythmia or arrhythmia requiring medication other than beta blocker Psychiatric illness/social situations that would limit compliance with study requirements Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, etc.) Concurrent malignancy or malignancy within 3 years prior to starting study drug, except: Malignancies that have completed therapy and are considered by their physician to be at less than 30% risk of relapse, or Malignancies not requiring treatment (e.g., RAI stage 0 chronic lymphocytic leukemia [CLL]) Central nervous system (CNS) involvement unless they meet ALL of the following criteria: At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea/vomiting/diarrhea, malabsorption syndrome, or major small bowel resection) Known history of human immunodeficiency virus (HIV) infection (testing not mandatory); NOTE: HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ribociclib; in addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated Systolic blood pressure (SBP) > 160 mmHg or < 90 mmHg at screening; if initial screening SBP is outside of the eligible range, blood pressure may be re-checked after intervention; SBP must be documented as stable and within the eligible range prior to starting study drug Currently receiving rivaroxaban, apixaban, endoxaban, warfarin or other warfarin derived anticoagulant; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed; if transitioning from a prohibited anticoagulant, a minimum washout of 7 days from last dose of the prohibited medication is required prior to ribociclib start Participation in a prior investigational interventional study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer Major surgery within 14 days prior to starting study drug or has not recovered from surgical complications (tumor biopsy is not considered as major surgery) History of congenital long QT syndrome or torsades de pointes History of non-compliance to medical regimen or inability to grant consent Pregnant or nursing (lactating) women; breastfeeding should be discontinued
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lara E Davis
Organizational Affiliation
OHSU Knight Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
OHSU Knight Cancer Institute
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

We'll reach out to this number within 24 hrs